当前位置: X-MOL 学术Clin. Cancer Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Crizotinib in ROS1 and MET Deregulated NSCLC--Response
Clinical Cancer Research ( IF 10.0 ) Pub Date : 2020-04-01 , DOI: 10.1158/1078-0432.ccr-20-0026
Lorenza Landi 1 , Rossella Bruno 2 , Gabriella Fontanini 2 , Federico Cappuzzo 1
Affiliation  

We thank the authors for their interest in our study and for their comments. Wiesweg and colleagues correctly reported that the minor allele frequency of both p.T1010I and p.R988C MET variants is close to 1% in the European population, but these mutations were described also as somatic (T1010I:

中文翻译:

克唑替尼在ROS1和MET失控的NSCLC中的反应

我们感谢作者对我们的研究感兴趣以及他们的评论。Wiesweg及其同事正确地报告了p.T1010I和p.R988C MET变体的次要等位基因频率在欧洲人群中接近1%,但是这些突变也被描述为体细胞性(T1010I:
更新日期:2020-04-01
down
wechat
bug